Evidence map›Paper›PMID 39424738›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Detection of Circulating Tumor DNA in Lymphoma Patients.

Alessio Bruscaggin, Katia Pini, Davide Rossi

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alessio BruscagginLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Katia PiniLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Davide RossiLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland. davide.rossi@eoc.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liquid biopsy has become an opportunity in lymphoma diagnostics, since plasma circulating tumor DNA (ctDNA) is an easily accessible source of tumor DNA, which can be complementary to tissue biopsy. Through ctDNA, lymphomas can be molecularly characterized, tumor clonal evolution can be tracked, while monitoring minimal residual diseases during and after therapy. Here, we describe the methodology of cancer personalized profiling by deep sequencing (CAPP-seq) that we use for ctDNA qualification and quantification.

Indexed as

Biomarkers, TumorCirculating Tumor DNAHigh-Throughput Nucleotide SequencingLymphomaHumansLiquid BiopsyPrecision MedicineBiomarkers, TumorCirculating Tumor DNACAPP-seqcfDNALiquid biopsyLymphomaNext-generation sequencingSomatic mutations

Identifiers

PMID39424738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.